Safety and Efficacy of the JAK Inhibitor Tofacitinib Citrate for Alopecia Areata and Variants
RNA-seq (gene expression) · human · 56 samples
- What it is
- RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
- Organism
- Homo sapiens (human)
- Samples
- 56 samples: 28 × pre vs 28 × postGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE80688_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.
Also filed as BioProject PRJNA319674 and SRA study SRP073940. Searching any of these in the dataset finder brings you back here.
Supports a between-group comparison across 56 samples.
How we read this: 2 replicated groups read from 56 sample titles; they account for 56 of them. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM2133490 pre28 pre
- GSM2133491 pre10 pre
- GSM2133492 pre6 pre
- GSM2133493 pre9 pre
- GSM2133494 pre24 pre
- GSM2133495 pre23 pre
- GSM2133496 pre12 pre
- GSM2133497 pre7 pre
- GSM2133498 pre3 pre
- GSM2133499 pre27 pre
- GSM2133500 pre25 pre
- GSM2133501 pre11 pre
- GSM2133502 pre22 pre
- GSM2133503 pre8 pre
- GSM2133504 pre4 pre
- GSM2133505 pre26 pre
- GSM2133506 pre18 pre
- GSM2133507 pre1 pre
- GSM2133508 pre19 pre
- GSM2133509 pre2 pre
- GSM2133510 pre20 pre
- GSM2133511 pre5 pre
- GSM2133512 pre17 pre
- GSM2133513 pre16 pre
- GSM2133514 pre15 pre
- GSM2133515 pre21 pre
- GSM2133516 pre14 pre
- GSM2133517 pre13 pre
- GSM2133518 post12 post
- GSM2133519 post27 post
- GSM2133520 post11 post
- GSM2133521 post26 post
- GSM2133522 post9 post
- GSM2133523 post8 post
- GSM2133524 post25 post
- GSM2133525 post7 post
- GSM2133526 post24 post
- GSM2133527 post6 post
- GSM2133528 post23 post
- GSM2133529 post5 post
+ 16 more — browse all 56 samples with per-sample file links →
- GSE296117 A single-cell RNA-seq dataset of synovial fluid from rheumatoid arthritis treated with TNF-α/JAK inhibitor 18 samples shares jak, inhibitor
- GSE281517 Lysosomal sequestration of PARP inhibitors drives heterogeneous accumulation in ovarian cancer to increase efficacy [RNA-seq] 72 samples shares inhibitor, efficacy
- GSE289185 Safety and efficacy of neoadjuvant radiotherapy and immunotherapy in the treatment of esophageal squamous cell carcinoma 29 samples shares efficacy, safety
- GSE301688 Preclinical Evaluation of the Efficacy of a Cyclin-dependent Kinase Inhibitor Ribociclib in Combination with Letrozole Against Patient-Derived Glioblastoma Cells 18 samples shares inhibitor, efficacy
- GSE325471 The CDK4/6 inhibitor dalpiciclib augments the antitumor efficacy of enzalutamide in preclinical models of castration-resistant prostate cancer through inhibition of MCM4-mediated DNA replication 12 samples shares inhibitor, efficacy
- GSE289713 Superior preclinical efficacy of co-treatment with BRG1/BRM and FLT3 inhibitor against AML cells with FLT3 mutations 11 samples shares inhibitor, efficacy
- GSE281556 Lysosomal sequestration of PARP inhibitors drives heterogeneous accumulation in ovarian cancer to increase efficacy 204 samples shares inhibitor, efficacy
- GSE300177 Catalytic inhibition of KAT6/KAT7 enhances the efficacy and overcomes primary and acquired resistance to Menin inhibitors in MLL leukaemia 194 samples shares inhibitor, efficacy
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.